EXACT Sciences News

Lionel N. Sterling has served as a director of Exact since 2010 and was reelected to the board.

Exact Sciences continues to wait for two critical gating events - FDA approval of the Cologuard test and CMS reimbursement for the test.

The firm currently has a "buy" rating on the stock. Canaccord Genuity's price target suggests a potential upside of 15.22% from the company's current price.

Good day, ladies and gentlemen, welcome to the Exact Sciences Second Quarter 2014 Earnings Conference Call.

Corp. priced a 10,000,000 share secondary stock offering at $12.75 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time and based on early trading on Tuesday, the stock is now 28.2% above the offering price.

The company's revenue had been comprised of the non-cash amortization of up-front license fee payments paid to it by Genzyme Corp. These payments were amortized over a five-year collaboration period that ended in during the same period of 2013.

Exact Sciences Corp. today announced that the company will host webcasts and conference calls to discuss its second-quarter 2014 financial results and of its annual meeting of stockholders.